Drug Discovery Innovation Programme (DDIP) EU 2026

Drug Discovery Innovation Programme (DDIP) EU 2026 is sponsored by World BI / Swiss Biotech Association (conference and networking focus, not direct grant funder). This opportunity supports mission-aligned projects and measurable outcomes.

Top Drug Discovery Conference 2026 – Basel | DDIP EU Standard passes are gone. Enter your name and email now to claim one of the final 2 tickets before this hold ends. Thank you.

Your ticket request has been sent. We will contact you shortly. No payment now.

We confirm your DDIP EU seat by email. ⚡ Existing World BI Customer? Claim Your Exclusive Loyalty Discount Now!

--> 🎟️ Limited Seats Available — Don't Miss out on Early Access! --> ⚡ Existing World BI Customer? Claim Your Exclusive Loyalty Discount Now!

--> 🎟️ Limited Seats Available — Don't Miss out on Early Access! --> Existing World BI Customer? Claim Your Exclusive Loyalty Discount Now!

Claim Now Movenpick Hotel Basel, Switzerland Drug Discovery Innovation Programme Where Drug Discovery Leaders Meet to Accelerate the Next Generation of Therapeutics 100+ R&D Executives, Discovery Scientists, and Innovation Leaders gathering for focused networking and knowledge exchange --> 12+ Hours of Insightful Sessions exploring emerging technologies, novel modalities, and transformative approaches in drug discovery --> 30+ Industry Experts and Thought Leaders sharing real world experiences and best practices from pharma and biotech --> 100+ R&D Executives, Discovery Scientists, and Innovation Leaders gathering for focused networking and knowledge exchange --> 12+ Hours of Insightful Sessions exploring emerging technologies, novel modalities, and transformative approaches in drug discovery --> 30+ Industry Experts and Thought Leaders sharing real world experiences and best practices from pharma and biotech --> September 29 – 30, 2026 --> Movenpick Hotel Basel, Switzerland --> Europe’s Strategic Drug Discovery Leadership Platform What is DDIP Europe 2026?

Where Drug Discovery Leaders Turn Ideas Into Breakthroughs The Drug Discovery Innovation Programme (DDIP) Europe brings together senior leaders from pharma, biotech, academia, and technology providers to explore the latest advances transforming drug discovery.

Through thought-provoking discussions, real-world case studies, and strategic networking, DDIP provides a platform for collaboration across AI, translational science, biologics, computational approaches, and emerging therapeutic modalities. Join the community of innovators accelerating the journey from breakthrough science to life-changing medicine. What is DDIP Europe 2026?

Advancing Innovation Across Drug Discovery in Europe DDIP Europe advances drug discovery through integrated science, advanced technologies, and cross-border collaboration for smarter development. We support a collaborative drug discovery ecosystem powered by AI and data-driven research to improve patient outcomes.

Where Pharma Meets Packaging Intelligence — Audience — DDIP EU 2026, Basel DDIP brings together senior leaders from pharma, biotech, academia and technology providers — spanning three tiers of decision-making across the drug discovery pipeline.

Chief Scientific Officers (CSOs) Biotech CEOs, Founders & Innovation Executives Heads, VPs & Directors of Drug Discovery Heads of Research & Development (R&D) Directors of Translational Medicine Discovery Biology Leaders Heads of Preclinical Development SPECIALIST & EMERGING DISCIPLINES Medicinal Chemistry Scientists and Leaders AI, Data Science & Computational Biology Experts Biologics and Novel Therapeutic Modality Leaders 120+ drug discovery leaders confirmed.

Request the list and we'll call you back within 24 hours. Get agenda, pass options & a callback in 24 hours. Select Inquiry Type * --> Select Inquiry Type * --> How Did You Hear About Us?

* --> How Did You Hear About Us?

* --> Other (Please Specify) --> Decision-makers, researchers, and innovators from across Europe’s pharma, biotech, academic, and regulatory communities, including: Senior Principal Scientist Industry Visionaries at DDIP A Platform of Discovery, Strategy, and Collaboration Senior Director Medicinal Chemistry Global Therapeutic Area Head - Infectious Diseases Longevity Biotechnology Strategic Partnering, BD & L Senior Director Chief Scientific Officer, Executive Vice President Associate Director and Sr Principle Data Scientist Novartis Biomedical Research Head of Translational AI & Target Discovery Lead Scientific Program Manager University Hospital Basel Senior Principal Scientist Senior Director Medicinal Chemistry Global Therapeutic Area Head - Infectious Diseases Longevity Biotechnology Strategic Partnering, BD & L Senior Director Chief Scientific Officer, Executive Vice President Associate Director and Sr Principle Data Scientist Novartis Biomedical Research Head of Translational AI & Target Discovery Lead Scientific Program Manager University Hospital Basel Pharma / Biotech / Non-Service Provider Attendees / Consultants / Service Providers Exhibitors / Vendors / Service Providers Get Your Pass & Unlock a Special Discount on the Networking Dinner!

Save 10% — Use Code WBISAVE Before Nov 25, 2026 Full Two-Days Conference and Exhibit Hall Ticket Access to In-Person Presentations and Panels All Inclusive Lunches and Refreshments Speed Networking Sessions Save 10% — Use Code WBISAVE Before Nov 25, 2026 Full Two-Days Conference and Exhibit Hall Ticket Access to In-Person Presentations and Panels All Inclusive Lunches and Refreshments Speed Networking Sessions Meet Our Trusted Sponsors 2026 Meet Our Trusted Sponsors Digital Marketing Partner Real Stories.

Real Impact. Hear It from Our Satisfied Clients The event was a fantastic and remarkable showcase of knowledge and Innovation. I was truly impressed by the diversity of topics and the excellence of the presentations.

Very impressionable. I enjoyed all the industry people and their talks and it was great meeting everybody. Emerging Innovations Unit It was a fantastic event to make new connections and engage with colleagues on emerging technologies and innovations.

Thank you to the Organizers. Focused small conference with insights across the DD process, from chemistry to manufacturing to cell viability prediction for Cart. Thanks to the DDIP team for putting together such a comprehensive and enlightening event!

Thank you for the invitation to speak. I had a very productive time and made some new, interesting connections. I will definitely look out for your upcoming conferences...

Biolexis Therapeutics, Inc. Everyone has done an excellent job in inviting speakers from various fields within the science of drug discovery. The talks are well-diversified, which is especially beneficial for me and our company. Biolexis Therapeutics, Inc. Everyone has done an excellent job in inviting speakers from various fields within the science of drug discovery.

The talks are well-diversified, which is especially beneficial for me and our company. Photo Collection From Past Events Digital Marketing Partner Speaker Acquisitions Executive speaking@worldbigroup. com For Sponsorship Enquiries sponsorship@worldbigroup.

com For Media Partnership Enquiries Media Partnerships Executive For Sponsorship Enquiries +44 20 3950 8884 , +44 74 2437 2809 Your details have been successfully submitted 😍. For Sponsorship Enquiries +44 20 3950 8884 , +44 74 2437 2809 Causaly is the leading Agentic AI research platform for life sciences, designed to accelerate R&D through scientifically grounded, autonomous research workflows.

Our agentic research capability orchestrates multi-step investigations by retrieving, analyzing, and synthesizing evidence across millions of scientific publications and data sources to deliver transparent, evidence-backed insights.

Built on a proprietary knowledge graph of over 500 million evidence points, Causaly enables researchers to uncover disease mechanisms, identify novel targets, evaluate biomarkers, assess safety signals, and understand the competitive landscape. Trusted by leading biopharma organizations, Causaly supports decision-making across the full R&D lifecycle.

From early discovery and translational research through clinical development and beyond, helping teams move from complex data to confident decisions faster. LIDE is an award winning oncology contract research organization with 14 years of delivering preclinical drug evaluation services to over 200+ clients worldwide. LIDE offers traditional CRO services for drug evaluation studies like organoids, CDX and PDX models.

It has a collection of more than 2300 patient derived xenograft models covering 50+ cancer types, of which 200+ are drug resistant and/or harbor interesting genetic alterations. LIDE's proprietary MiniPDX and IO-FIVE tools offer an evolved approach to drug R&D that maximizes budget efficiency and minimizes time to validation.

The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment. nuantic is a Swiss biotech company using AI to accelerate therapeutic protein and peptide engineering.

Its technology efficiently explores the protein sequence space to identify optimized candidates with improved properties, reaching optimization goals such as improved affinity, developability or function often in a single round with 30-90 variants. Scantox is an integrated preclinical CRO supporting sponsors from discovery through IND-enabling nonclinical development, with operations in Denmark, Sweden, Austria, and the United Kingdom.

We combine Discovery, Regulatory Toxicology, and Pharmaceutical Development & Analytical in one coordinated platform - helping clients generate high-quality, regulator-ready data while keeping timelines and execution aligned across disciplines. Scantox is recognized for deep expertise in CNS pharmacology and Göttingen minipig research, with advanced genetic toxicology capabilities including Big Blue® transgenic rodent assays.

Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company. Genedata’s mission is to empower biopharma worldwide to innovate boldly, operate efficiently, and accelerate discovery, development, and manufacturing of next-generation medicines. Genedata transforms biopharma data into intelligence.

Our innovative software solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions.

From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI being trusted by customers worldwide for more than 25 years. CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies.

We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs.

CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us. intoDNA is a global precision medicine company that provides biopharma and clinicians with decision-grade insights into DNA damage and repair biology to reduce risk, accelerate timelines, and enable truly precise patient care.

Our patented STRIDE® platform delivers single-cell resolution combined with advanced AI-driven data analysis, producing unique, objective, high-sensitivity results validated across therapeutic areas. We know existing modalities can fall short, and we envision a future where the right therapies reach the right patients, at the right time.

The STRIDE technology detects and quantifies DNA damage and repair in situ, down to the individual lesion, powering biomarker discovery, target validation, pharmacodynamic studies, and response prediction across DNA Damage Response, radiotherapeutics, immuno-oncology, and antibody-drug conjugate development.

Trusted by leading academic centers and biopharma innovators worldwide, intoDNA delivers this data from early discovery through Phase III, helping teams move faster toward safer, more effective therapies for the patients who need them. Isogenica is a Cambridge-based biotechnology CRO specialising in VHH single-domain antibody discovery for next-generation biologics.

We help biotech and biopharma R&D teams tackle the targets that stall conventional discovery – targets and projects that require specialised antigen and discovery techniques like multipass transmembrane targets and intracellular targets.

Backed by the most diverse synthetic VHH libraries available, we work to cut typical discovery timelines in half by accelerating lead selection and reducing downstream engineering rework, giving discovery teams faster access to developable binders for therapeutics, bi-specifics, ADCs, T-cell engagers and other advanced formats.

With 25+ years of discovery experience, well over 100+ programmes delivered and multiple candidates progressed into clinical trials, we work as a genuine extension of partner teams from early discovery through lead selection and engineering. For teams building novel modality or translational programmes around difficult biology, we help reduce early-stage risk and reach key development milestones with fewer surprises downstream.

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.

To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™. InSilicoMinds is an AI-driven computational modeling and simulation company accelerating pharmaceutical research and development through advanced in silico technologies.

We partner with biotechnology, pharmaceutical, and life sciences organizations to improve decision-making across drug discovery, preclinical research, clinical development, and regulatory submissions. Our expertise spans molecular modeling, molecular dynamics, PBPK modeling, population PK (PopPK), quantitative systems pharmacology (QSP), AI-driven drug discovery, virtual bioequivalence, and regulatory modeling.

We combine scientific expertise with artificial intelligence to identify promising drug candidates, optimize formulations, predict clinical outcomes, and reduce development timelines and costs. In addition, we develop intelligent AI copilots and knowledge platforms that automate scientific workflows, streamline data assembly, and enhance productivity for modeling and regulatory teams.

By integrating computational science, machine learning, and deep pharmaceutical expertise, InSilicoMinds enables faster, data-driven R&D decisions, helping clients accelerate innovation while improving confidence, efficiency, and the probability of technical and regulatory success.

At Healthcare Business Outlook Magazine, our mission is simple yet profound: to empower healthcare professionals with the knowledge, insights, and best practices they need to succeed in today’s rapidly changing landscape.

We understand that a healthcare facility is not just about providing exceptional patient care—it’s also about navigating complex regulatory environments, optimizing financial performance, and leveraging technology to drive efficiency and innovation. Pharma Business Outlook is more than just a publication, it is a bridge that connects pharmaceutical companies, healthcare providers, and key decision-makers.

By fostering discussions on regulatory compliance, emerging market opportunities, and digital transformation, the magazine plays a crucial role in shaping the future of the pharmaceutical ecosystem. Whether exploring the latest innovations in clinical trials or uncovering strategies to enhance patient outcomes, Pharma Business Outlook remains a trusted resource for professionals committed to advancing the industry.

Medhealth Outlook serves as the backdoor to the latest technologies and trends in the healthcare, pharma, and medical industries. The publication follows an inside/outside approach that allows viewers to witness varied and balanced perspectives. Medical Business Outlook Magazine is a platform dedicated to exploring the growing medical business arena and the solutions that drive it forward.

With a sharp focus on medical business operations, strategies, and innovations, the magazine serves as a trusted resource for executives, medical decision-makers, and medical professionals seeking to stay informed and ahead of the curve. Life Sciences Business Outlook is a premier platform dedicated to showcasing the innovations, advancements, and transformative solutions shaping the life sciences industry.

Our magazine serves as a beacon for businesses and professionals seeking cutting-edge insights and actionable strategies to stay ahead in this dynamic sector. Healthcare Tech Outlook, a print platform offering healthcare decision-makers critical information on adopting, innovating, and building new programs and approaches to enhance their capability to provide care.

Healthcare Tech Outlook has been a pioneer in offering a learn-from-peer approach to the healthcare arena, offering technical advice to enhance both the overall healthcare landscape and assist individual care providers from general practitioners and specialists to post-acute care organizations. Gubra is a disease-agnostic company specializing in peptide-based drug discovery and preclinical contract research services.

Operating through three synergistic business units, Biotech, CRO, and Ventures, we combine scientific excellence with strong value creation and a firm commitment to society. Our team of approximately 300 employees collaborates with industry and academia to improve the quality of people’s lives.

We are part of Piramal Pharma Solutions (PPS) which is a Contract Research Development and Manufacturing Organization (CDMO) offering end-to-end discovery, development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.

This enables us to offer a comprehensive range of services including Drug Discovery solutions, Process & Pharmaceutical Development Services, Clinical Trial Supplies, Commercial Supply of APIs, and Finished Dosage Forms .

The Discovery Services site of PPS has been operational since 2003 in Ahmedabad, India and currently has ~300+ chemistry FTEs and ~30 Biologists for screening and ADME supporting various small molecule discovery programs in Hit to Lead and Lead Optimization stages. Our services are available on both FTE and Fee Based Models (FFS).

Our capabilities include: Custom Synthesis of individual compounds, building blocks, scaffolds, focused libraries (40 -100 compounds), reference standards, intermediates, impurities & metabolites Route Scouting, leveraging our global process chemistry expertise across US, Canada & India to support early drug development Analytical services, including method development (non-GMP) and separation of Chiral/ Achiral compounds (mg-gm scale) PPS also offers specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product from 15 sites in India, UK, Canada and USA.

Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.

Since 2002, Affygility Solutions has provided occupational toxicology, industrial hygiene, and occupational health and safety services to the biotechnology, pharmaceutical, and medical device industries. Trusted by more than 800 clients across 75+ countries, Affygility helps organizations simplify complex compliance processes, protect worker safety, and accelerate product development timelines.

Its services include Occupational Exposure Limits (OELs), Acceptable Daily Exposure (ADE) values, Occupational Health Categorization (OHC) reports, Safety Data Sheets (SDSs), and custom toxicology monographs for proprietary compounds. Through its OEL Fastrac+ platform, Affygility delivers fast, accurate toxicology data to support cleaning validation, manufacturing, and regulatory compliance decisions.

With an international team based in the United States, Canada, Brazil, Singapore, and the United Arab Emirates, Affygility combines deep scientific expertise with innovative technology to support life sciences organizations worldwide. Maxwell Biosciences has developed technology that can mimic 10,000+ peptides that naturally exist in the human body, a biomimetic immune system.

Our vision is to create health for the world, safely and affordably. Our peptide mimics (Claromers®) have the ability to destroy pathogenic viruses, fungi, bacteria and biofilms without harming healthy cells. Claromers are shelf-stable, microbiome-resilient and low cost.

Originally developed for critical infectious diseases, Maxwell’s technology is now entering non-pharmaceutical commercial deployment across cosmetics, personal care, medical coatings and biodefense—with pilot access for select partners.

Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active collaborative agreements with the US military and governments worldwide. FDA clinical trials are planned for 2026. Maxwell’s AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable solutions for a healthier planet.

Biocytogen is a global biotech company that drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ authentic antibody sequences through its RenBiologicsTM sub-brand for partnerships. Biocytogen is advancing antibody drug development through innovative technologies.

Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 4,000+ models via BioMiceTM, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services.

Sai Life Sciences is an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO) that works with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness.

The company has over 3,400 employees across its facilities in India, UK, USA and Japan. BioGenes: Superior Services in Life Sciences since 1992 BioGenes GmbH, founded in 1992 in Berlin, is an ISO9001:2015 certified top-level service provider offering customised immunoassay and antibody development as well as analytical services in our in-house facilities.

BioGenes has served over 5000+ customers worldwide which includes large and medium-sized pharma and life-science companies as well as CMOs/CROs. Our returning customers are a proof of our scientific excellence, international quality standards and transparent processes.

Our key service areas include: Customized development of monoclonal, polyclonal and anti-idiotypic antibodies Host Cell Protein (HCP) ELISA development Generic HCP ELISA kits - for E.

coli, CHO and HEK293 High Risk HCP ELISA Kits - for PLBL2, PRDX1 and CTSB HCP analytics from 2D DIGE to Western Blot Immunoassay production services (OEM production) of small and medium sized lots Pharmacokinetics & Immunogenicity assay development The application areas of our services and products are clinical development, testing and production of biological therapeutics such as vaccines and biopharmaceutical drugs in pre-clinical and/or clinical phase.

Our 70+ strong team of specialists make sure we never lose track of our main mission: the best results for our customers. Our flexible work packages and scalable manufacturing caters to customer timelines with intensive project management from start to finish. With a dedicated team of 70+ specialists, we are committed to delivering the best possible outcomes for our clients.

Our project management team works closely with you from the initial consultation through to project completion, ensuring transparency, communication, and flexibility at every stage. Whether you need small-scale, pilot production or larger-scale manufacturing, we have the capabilities to support your goals.

IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate.

With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions.

Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields. Instant access. Secure checkout.

VIP slots have been filled All complimentary VIP allocations have currently been filled. Want to be notified if a slot opens? You're on the list.

We'll email you if a VIP slot opens. Instant access. Secure checkout.